Kidney PATIENT Act of 2023

This bill delays a Medicare policy that would have restricted coverage to only intravenous drugs for managing phosphate levels in kidney failure patients. It specifically postpones the implementation of the "oral-only" policy under Medicare's ESRD payment system until January 1, 2033, or until an intravenous drug for phosphate control receives FDA approval - whichever comes first. The bill directly affects Medicare beneficiaries with end-stage renal disease (ESRD) who rely on oral medications for phosphate management. It ensures continued Medicare coverage for these oral drugs during the extended timeline, without changing the underlying payment structure.